Dostarlimab, a PD-1 inhibitor, is being evaluated in a Phase 4 trial for its safety in adult patients with dMMR/MSI-H recurrent or advanced endometrial cancer in India. This study is significant as it targets a specific patient population that has limited treatment options following platinum-based therapies. The Indian market for oncology therapeutics is growing, and successful outcomes could enhance GSK's positioning in the immuno-oncology space, particularly in emerging markets. The trial's non-comparative design may limit direct competitive insights but could provide valuable safety data that supports broader use of dostarlimab in this indication. The estimated enrollment of 100 patients indicates a focused approach, potentially allowing for quicker data collection and analysis.